sufficient sample sizes to compare treatment strategies with robust clinical end points may be challenging to achieve within a timeframe of clinical relevance. A proposed solution to these problems is greater use of large streamlined clinical trials, characterized as those that examine clinically relevant alternative treatments, include broad patient populations, and recruit patients from diverse practice settings with fewer protocol-defined specifications for data collection and site monitoring. 7, 8 In 2007, concerns arose on the occurrence of stent thrombosis in patients receiving drug-eluting stents (DES) for percutaneous coronary intervention. Existing RCT data were largely from narrowly defined patient populations, often excluding patients with myocardial infarction or complex lesion anatomy, despite the reality that the large majority of such patients in routine clinical practice were being treated with DES. To address the public health concern about the prevention of stent thrombosis and its clinical sequelae such as death and myocardial infarction, the US Food and Drug Administration requested randomized trial data comparing different durations of dual antiplatelet therapy (DAPT). The DAPT Study was designed as a large streamlined trial with few exclusion criteria to enroll a broad cohort of subjects undergoing percutaneous coronary intervention (PCI) with any Food and Drug Administration-approved DES. 9 Although large streamlined clinical trials would seem advantageous for generating broadly generalizable results to help inform clinical decision making, few studies have examined whether such trials succeed in including hospitals and patients that are representative of routine practice environments. We therefore sought to determine whether the sites and subjects enrolled in the US DAPT Study were similar to typical PCI hospitals and patients in the United States, as reflected by the National Cardiovascular Data Registry (NCDR) CathPCI Registry.
Methods
We performed 2 main comparisons: (1) 
The DAPT Study
The DAPT Study is an international, multicenter, RCT that compared 30 versus 12 months of DAPT after PCI with coronary stents. The rationale and design of the DAPT Study have been described previously. 9 Inclusion criteria for the trial were purposefully broad to evaluate DES-treated subjects representative of patients seen in routine clinical practice. The study included subjects >18 years of age undergoing PCI with a Food and Drug Administration-approved stent. The main exclusion criteria were planned surgery requiring discontinuation of antiplatelet therapy within 30 months after enrollment, pregnancy, life expectancy <3 years, concomitant use of warfarin or another anticoagulant, and hypersensitivity or allergy to any component of DAPT. For this analysis, all DES-treated subjects enrolled in the DAPT Study from sites within the United States were included (herein referred to as the DAPT-enrolled population). Study enrollment commenced on September 1, 2009 and completed on July 1, 2011.
NCDR: CathPCI Registry
The CathPCI is registry cosponsored by the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions and includes >1200 hospitals in all 50 US states, contributing data on >600 000 PCI procedures per year. 10 Data submitted to the registry are filtered for completeness and consistency, and a random sample of records are audited annually. 11 CathPCI hospitals represent more than three quarters of all PCI-performing hospitals in the United States, as identified by American Hospital Association. 12 We identified hospitals participating in the registry and registry patients who underwent PCI with DES from September 1, 2009 through July 1, 2011, contemporaneous with the enrollment period of the DAPT Study. Because unique identifiers are not submitted to the NCDR CathPCI registries, individuals undergoing multiple procedures during the study period may be represented more than once in the data set.
Statistical Analysis

Participating versus Nonparticipating Hospital Comparison
We compared hospital and patient characteristics between hospitals that participated in the DAPT Study versus hospitals that did not participate, among those hospitals contributing data to the NCDR CathPCI Registry. All PCI procedures were included in this comparison independent of stent type or procedure indication. To identify DAPT sites within the NCDR CathPCI Registry, we first linked each DAPT site with the corresponding hospital where cardiac catheterizations were performed. Sites that performed PCI at >3 locations without a clearly dominant location, as well as those that could not be linked to a hospital, were excluded from this study. The hospital list of DAPT Study sites was then cross-matched with a list of
WHAT IS KNOWN
• Randomized clinical trials have historically been limited by the enrollment of highly selected populations, lack of feasibility, and high costs.
• Streamlined trials, such as the Dual Antiplatelet Therapy Study, use limited exclusion criteria and less onerous protocols for data collection and site monitoring to rapidly enroll broadly representative populations.
WHAT THE STUDY ADDS
• The Dual Antiplatelet Therapy Study, the largest streamlined randomized study of patients undergoing percutaneous coronary intervention to date, involved a large proportion of US hospitals with similar patient populations and outcomes as those not participating in the trial. • Patients enrolling in the trial were similar to those undergoing percutaneous coronary intervention within the National Cardiovascular Data Registry with respect to race, sex, and most comorbidities, although rates of prior cardiovascular disease were lower in Dual Antiplatelet Therapy Study patients. • Although a streamlined cardiovascular clinical trial may successfully involve a large number of hospitals and rapidly enroll a diverse population of patients, differences between eligible patients and those actually enrolled remained. January 2015
CathPCI-participating hospitals during the period of DAPT Study enrollment. Information was gathered through a mix of web searches, communications with site principal investigators and research coordinators, and direct telephone communications with hospital catheterization laboratories. A wide range of characteristics were compared among patients at DAPT-participating hospitals versus nonparticipating hospitals, including demographic characteristics, medical history, presenting symptoms, and in-hospital outcomes. The characteristics and outcomes were drawn from data collected by the NCDR CathPCI Registry, and definitions of the data elements are available at https:// www.ncdr.com/webncdr/cathpci/home/datacollection. Hospital characteristics were compared between these groups and included number of beds, location and community type, profit type, association with a fellowship, internship, or residency program, geographical region, annual PCI volume, and the number of physicians performing PCI procedures.
Enrolled Versus Eligible Patient Comparison
We compared characteristics between enrolled DAPT Study subjects versus the population of NCDR CathPCI Registry patients undergoing PCI with DES who may have been eligible for enrollment based on the trial's inclusion/exclusion criteria (DAPT-eligible patients). To exclude NCDR CathPCI Registry patients who would not have been eligible for the DES arms of the DAPT Study, we excluded patients not prescribed a thienopyridine at discharge. Because data on pregnancy, life expectancy, and concurrent warfarin therapy were not available within the CathPCI Registry, these DAPT Study exclusion criteria were not applied to the CathPCI Registry population.
Enrolled DAPT subjects were compared with DAPT-eligible registry patients for selected characteristics that were similarly defined and recorded in the DAPT Study and the NCDR CathPCI Registry. These data elements included sociodemographic information (age, sex, race, and ethnicity); medical history (body mass index, diabetes mellitus, and smoking); cardiovascular history (hypertension, prior myocardial infarction [MI], prior congestive heart failure, peripheral vascular disease, prior PCI, and prior coronary artery bypass grafting [CABG]); presentation (non-ST-segment-elevation myocardial infarction or ST-segment-elevation myocardial infarction); and procedural characteristics (treated vessel and thienopyridine therapy at discharge). Because of the lack of patient identifiers, we could not identify individual subjects enrolled in the DAPT Study within NCDR CathPCI data to exclude them from the registry group. However, because of the large number of registry patients compared with trial enrollees, this is unlikely to influence the comparison. We also repeated this comparison limiting the population to those undergoing PCI within DAPT-participating hospitals.
All comparisons were made using standardized differences because of the large sample sizes, which may render comparisons via P values less useful. 13 By convention, standardized differences of >10% were considered significant. All analyses were conducted using SAS version 9. Analyses by the NCDR were approved by Chesapeake Research Review, Inc and supported by the Duke Clinical Research Institute. 
Results
DAPT-Participating Versus Nonparticipating Hospitals
Patient characteristics for PCIs at DAPT-participating hospitals were no different from those at nonparticipating hospitals. There were no significant differences in demographics, comorbidities, admission symptoms, indications for PCI, or procedural characteristics between the 2 groups (Tables I and  II in the Data Supplement) .
However, there were marked differences with regard to hospital characteristics between DAPT-participating and nonparticipating hospitals (Table 1) . Hospitals participating in DAPT were more frequently located in an urban setting (61.2% versus 42.6%; standardized difference, 37.8%), located in the Northeast (19.1% versus 11.4%; standardized difference, 21.6%), and affiliated with an internship, residency, or fellowship program (53.7% versus 34.1%; standardized difference, 40.3%). Furthermore, DAPT-participating hospitals had more beds (468±242 versus 311±182; standardized difference, 73.3%), had a higher average annual PCI volume (858±533 procedures versus 378±328; standardized difference, 108.6%), and had more physicians performing PCI procedures (14.6±9.5 versus 10.3±7.0; standardized difference, 51.3%). Participating hospitals were less frequently private or community hospitals compared with nonparticipating hospitals (80.6% versus 93.2%; standardized difference, −38.0%).
Crude inhospital mortality rates after PCI were not different at DAPT-participating hospitals compared with nonparticipating hospitals (1.30% versus 1.45%; standardized difference, 1.3%). Unadjusted bleeding rates within 72 hours after PCI were also not different ( Table 2) .
DAPT-Enrolled DES Patients Versus US DES Patients
Patients undergoing PCI with DES who were enrolled in the DAPT Study were not different from patients contemporaneously undergoing PCI with DES within the NCDR Cath-PCI Registry with respect to race and sex, as well as clinical characteristics such as diabetes mellitus and hypertension. (Table 3 ) Patients enrolled in the trial were younger than registry patients (62.2±10.6 versus 64.3±11.6 years; standardized difference, −19.2%), and prior cardiovascular history, including history of peripheral vascular disease, congestive heart failure, myocardial infarction, and prior PCI and coronary artery bypass grafting, was less frequent in DAPT-enrolled patients compared with NCDR CathPCI patients. With regard to procedural characteristics, patients enrolled in the DAPT Study were less likely to have multivessel PCI (11.1% versus 15.0%; standardized difference, −11.8%), but rates of left main coronary artery stenting and vein graft procedures were not different ( Table 4 ). Length of stay was significantly shorter in enrolled patients compared with those eligible. Patients enrolled in DAPT more often received paclitaxel-eluting stents and were more frequently discharged on prasugrel compared with eligible patients within the NCDR, as one of the clinical studies contributing to DAPT mandated use of these 2 in combination. 14 Similar results were seen when the NCDR population was limited to those hospitals that participated in the DAPT study (Tables III and IV in the Data Supplement) .
Discussion
There has been an increased awareness of the limitations of traditional RCTs to inform clinically relevant decisions faced by physicians. Although observational studies using registry or claims data may often overcome some of these limitations through the inclusion of large populations of unselected patients, 15 they introduce the potential for confounding. More recently, there have been calls for trials occupying a middle ground, ranging from streamlined trials that may use risk based rather than comprehensive site-monitoring strategies and limited central event adjudication 8 to pragmatic or practical trials that may forgo these elements. 7 Common to all such trials, however, are the goals to specifically to answer the questions faced by decision makers, 7 the incorporation of standard clinical alternatives to the intervention of interest, the use of purposefully broad inclusion criteria with minimal exclusions, and the preservation of randomization to minimize bias. The DAPT Study, the largest randomized trial of PCI patients to date, was designed as 1 such trial. 9 The goal of this study was to assess whether the study design and execution resulted in the inclusion of hospitals and patients representative of those seen in clinical practice.
We found that the DAPT Study involved a large percentage of US hospitals and that DAPT-participating hospitals had similar outcomes to nonparticipating hospitals. Participating hospitals tended to be larger, academic hospitals with higher procedural volumes and were more often located in urban settings compared with nonparticipating hospitals. Although most hospitals were located in the South among both groups, there was a higher prevalence of hospitals in the Northeast among participating versus nonparticipating centers. The observed differences in hospital characteristics between participating and nonparticipating sites may represent targeting sites that serve a larger and more geographically concentrated population of patients to enable more rapid enrollment and ensure timely study completion and dissemination of results. Further examination into the characteristics of smaller rural hospitals that nevertheless participated in the trial may improve our ability to broaden the number centers that participate in clinical research and further enhance the generalizability of research findings.
The inability to enroll sufficient numbers of women and minority patients has been a significant critique of prior RCTs. [3] [4] [5] [6] [16] [17] [18] We found that the DAPT Study was able to enroll a population of patients who were similar with respect to race and sex as those patients undergoing PCI with DES in the community. Patients enrolled in the study also underwent similar rates of complex procedures such as vein graft and left main interventions. However, DAPT-enrolled patients tended to be younger and have lower cardiovascular disease burden than US PCI patients, as well as shorter lengths of stay. There are multiple possible mechanisms for this difference, including subjects' views on informed consent for a randomized trial or the investigators perception on a subject's ability to comply with the trial protocol. The presence of screening and consent procedures has been found to bias trials toward inclusion of healthier subjects than observed in general practice even in studies intended to be broadly inclusive. 19, 20 Although we observed that the adjusted outcomes for hospitals did not differ between participating and nonparticipating hospitals, determining how clinical trial results might be formally adjusted to reflect practice in the general population is an area warranting further investigation. Values are percentage or mean±SD. BMI indicates body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; DAPT, Dual Antiplatelet Therapy; DES, drug-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction.
A major strength of this study is the ability to link study sites within a large comprehensive national registry with a large clinical trial. As a result, we were able to critically examine challenges to the generalizability of a large clinical trial in a manner not otherwise possible. We believe that this study is the first to formally examine whether a representative group of practice settings and patients can be achieved in a large trial of this type. Furthermore, clinical trials embedded in registries have been promoted as a potential solution to improving the generalizability and feasibility of conducting randomized trials. [21] [22] [23] For example, the Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial evaluated the role of aspiration thrombectomy among patient with ST-segment-elevation myocardial infarction using routinely collected baseline and outcome data from a comprehensive national registry. 22 Similarly, the Study of Access site for Enhancement of PCI for Women (SAFE-PCI) used the NCDR CathPCI Registry to identify sites with sufficient radial artery catheterization experience and leveraged existing data collection forms to increase the efficiency of trial enrollment and execution. 23, 24 We think our study further highlights the potential uses of registry data to inform clinical trial external validity and address a key critique of RCTs.
However, there are several limitations to our study. First, we were not able to apply all of the DAPT Study exclusion criteria to the NCDR CathPCI Registry population as certain information (pregnancy, life expectancy <3 years, and concurrent warfarin or other anticoagulant therapy) was not available from the registry. The lack of information on oral anticoagulation in the NCDR is notable, as its prevalence may differ substantially between trial patients and NCDR patients. However, by limiting the cohort to DES subjects for the comparison of DAPT-enrolled versus eligible patients, we think we have likely excluded a large number of patients on chronic anticoagulation for whom some guidelines recommend BMS for PCI. 25, 26 Nevertheless, the inability to exclude such patients from the NCDR CathPCI sample may explain some of the observed imbalance in baseline comorbidities and demographic characteristics or contribute to unobserved differences between groups. Next, although the DAPT study is the largest randomized postmarketing study of coronary stents conducted to date, it may not be representative of clinical trials in other disciplines or other cardiovascular trials conducted in a different manner. In addition, although the NCDR CathPCI Registry includes the large majority of PCI-performing hospitals in the United States, systematic differences may exist between included and excluded hospitals, such as those that are part of the Veteran's Administration system. Data from the NCDR registries are site generated and not comprehensively subject to querying or adjudication for accuracy. Furthermore, the DAPT Study includes randomization to prolonged DAPT or placebo 12 months after enrollment. However, because we did not have data on NCDR CathPCI patients 12 months after their procedures, we were not able to compare the DAPT Study randomized population to similar patients who might have been eligible for randomization had they participated in the study. Next, because the NCDR does not include unique patient identifiers, patients may be represented more than once in the data set. Finally, because of large sample size within the NCDR population, we used standardized differences to examine differences between groups, with a cutoff of 10% for significance. Other methods and cutoffs for statistical significance could have been selected.
In conclusion, we demonstrate that a large streamlined clinical trial can be conducted in a manner that involves a large number of hospitals, enrolls rapidly, and includes a diverse population of patients while also preserving key design features to minimize bias: randomization and central adjudication. Although sites participating in such a trial had similar adjusted clinical outcomes, they still differ from nonparticipating sites in many ways, a factor which should be considered when generalizing results to clinical practice. In addition, patient enrolled in the DAPT Study were, on average, a lower risk population compared with potentially eligible patients, despite limited exclusion criteria. These findings have important implications for the evaluation and interpretation of large inclusive randomized trials.
Sources of Funding
Funding for the Dual Antiplatelet Therapy (DAPT) Study is provided by four US manufacturers of drug-eluting stents (Abbott Vascular, Boston Scientific, Cordis, and Medtronic Cardiovascular) and the current manufacturers of thienopyridine medications (Eli Lilly/Daiichii Values are percentage unless otherwise noted. Missing data were <4% for all elements. DAPT indicates Dual Antiplatelet Therapy; DES, drug-eluting stent; LAD, left anterior descending; and PCI, percutaneous coronary intervention.
*One of the 4 manufacturer-sponsored studies contributing to the DAPT Study mandated treatment with prasugrel after PCI.
